Bristol Myers Squibb International Corporation

Research activity includes non-small cell lung cancer across operable, locally advanced, metastatic, and stage IV settings, as well as small cell lung cancer in extensive-stage disease. The portfolio also extends to early-stage and resected lung cancer, with attention to immunotherapy and combination treatment approaches.

• Non-small cell lung cancer
• Small cell lung cancer
• Early-stage and resected lung cancer
• Metastatic thoracic malignancies

These studies reflect sustained interest in lung cancer control across both curative-intent and advanced disease settings.